期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他克莫司治疗慢代谢型重症肌无力的疗效 被引量：10

下载PDF
导出
摘要 目的探讨CYP3A5基因型为GG型重症肌无力(MG)患者(Ⅰ/Ⅱ型)他克莫司(FK506)个体化治疗的疗效评价及其与血药浓度的关系。方法选取Ⅰ/Ⅱ型MG患者进行CYP3A5基因型检测,对27例乙酰胆碱受体抗体(AchR-Ab)阳性、CYP3A5基因型为GG型的MG患者予小剂量FK506治疗前、加药过程中及症状改善后分别进行临床评分、疗效评价和血药浓度测定。并在治疗前后进行AchR-Ab检测。结果 FK506治疗3个月后MG患者的临床绝对计分较治疗前明显降低(P<0.01),临床有效率达88.9%(24/27),AchR-Ab也较治疗前下降(P<0.05),相对计分≥50%时,血药浓度总体均数的95%CI为4.018～5.411 ng/mL。结论 CYP3A5基因型为GG型的MG患者采用FK506治疗后临床症状改善较好,安全有效,降低了AchR-Ab的水平,值得临床广泛应用。
作者 裴耀华 王磊 史延锋 王琦
机构地区 辽宁医学院研究生学院 中国人民解放军第二炮兵总医院神经内科
出处 《广东医学》 CAS CSCD 北大核心 2012年第7期1004-1005,共2页 Guangdong Medical Journal
关键词 CYP3A5 重症肌无力 他克莫司 乙酰胆碱受体抗体
分类号 R544.1 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1SELA M, MOZES E. Therapeutic vaccines in autoimmunity [ J ]. Proc Natl Acad Sci U S A, 2004, 101(2) : 14586 -14592.
  • 2PASEUZZI R M, COSLETY H B, JOHNST R. Long- term cortieosteroid treatment of myasthenia gravls: report of 116 patients [J]. Ann Neurol, 1984, 15(3) : 291 -298.
  • 3KINO T, HATANAKA H, MIYATA S I, et al. FK -506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effeet of FK - 506 in vitro [ J ]. J Antibiot ( Tokyo ), 1987, 40(9) : 1256 -1265.
  • 4YOSHIKAWA H, IWASA K, SATOH K, et al. Treament of severe and difficult cases of systenfie lupus erythematosus with tacrolimus. A report of three cases[J]. J Autoimmun, 1997, 10 (1): 11-16.
  • 5KONISHI T, YOSHIYAMA Y, TAKAMORI M, et al. Clinical study of FK506 in patients with myasthenia gravis [ J ]. Muscle Nerve, 2003, 28(5) : 570 -574.
  • 6WAKATA N, SAITO T, TANAKA S, et al. Tacrolimus hydrate (FKS06) : therapeutic effects and selection of responders in the treatment of myasthenia gravis [ J ]. Clin Neurol Neurosurg, 2003, 106(I): 5-8.
  • 7赵重波,朱雯华,卢家红.小剂量他克莫司治疗难治性全身型重症肌无力的初步研究[J].中国临床神经科学,2005,13(4):406-409. 被引量：16
  • 8陈艳梅,刘丽宏,王熙然,李鹏飞,马萍,童卫杭,丁春雷.健康受试者他克莫司代谢与CYP3A5基因多态性的相关性[J].山东医药,2009,49(9):28-30. 被引量：5

二级参考文献34

  • 1Clase CM, Mahalati K, Kibcrd BA, et al. Adequate early cyclos- porin ex'posure is critical to prevent renal allograft rejection : patients monitored by absorption profiling [ J ]. Am J Transplant, 2002,2 (8) :789-795.
  • 2Evans WE, MeLeod HL. Pharmaeogenomics-drug disposition, drug targets, and side effects[J]. N Engl J Meal, 2003,34-8(6):538- 549.
  • 3Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of genetic basis of polymorphie CYP3A5 expression[J]. Nat Genet, 2001,27(4) :383-391.
  • 4Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 hapotypes in a Japanese population[J]. Hum Mutat, 2004,23(1) :100.
  • 5Xie HG, Wood AJ, Kim RB, ct al. Genetic variability in CYP3A5 and its possible consequences [ J ]. Pharmacogenomics, 2004, 5 (3) :243-272.
  • 6Dai Y, Hebert MF, Isohemmen N, et al. Effect of CYP 33,5 polymorphism on tacrolimus metabolic clearance in vitro [ J]. Drug Metab Dispos, 2006,34(5) :836-847.
  • 7Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimu8 trough levels in living-donor liver transplant recipients[J ]. Phannacogenet C, enomics, 2006,16 (2) : 119- 127.
  • 8Satoh S, Kagaya H, Saito M, et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients[ J]. Br J Clin Phannacol, 2008,66(2) :207-214.
  • 9Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus [ J]. Transplant Proc, 2005,37 ( 1 ) : 178-181.
  • 10Roy JN, Barama A, Poirier C, ct al. CYP3A4, YP3AS,and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients[J]. Pharmacogenet C, enomics, 2006,16(9) : 6594565.

共引文献19

同被引文献128

  • 1赵重波,朱雯华,卢家红.小剂量他克莫司治疗难治性全身型重症肌无力的初步研究[J].中国临床神经科学,2005,13(4):406-409. 被引量：16
  • 2丛志强,李海峰.重视重症肌无力的临床诊断[J].中华神经科杂志,2006,39(11):786-788. 被引量：15
  • 3陈珉,陈子爱.免疫球蛋白治疗重症肌无力的安全及有效性观察[J].实用全科医学,2007,5(4):302-303. 被引量：5
  • 4许贤豪.神经免疫学[M].北京：北京医科大学中国协和医科大学联合出版社,1992.113.
  • 5Chris T.A review of myasthenia gravis Pathogenesis,clinical featuresand treatment[J].Curr Anaesth Crit Care,2007,18(1):15-23.
  • 6Schneider-Gold C,Gajdos P,Toyka KV,et al.Corticosteroids formyasthenia gravis[J].Cochrane Database Syst Rev,2005,18(2):CD002828.
  • 7Sanders DB,Hart JK,Mantegazza R,et al.An international,phaseⅢ,randomized trial of mycophenalate mofetil in myastheniagravis[J].Neurology,2008,71(6):400-406.
  • 8Hehir MK,Burns TM,Alpers J,et al.Mycophenalate mofetil inAChR-antibody-positive myasthenia gravis:outcomes in 102 patients[J].Muscle Nerve,2010,41(5):593-598.
  • 9Naoki K,Satoshi K,Yuko N,et al.Effects of thymectomy on late-onset myasthenia gravis without thymoma[J].Clin Neurol Neuro-surg,2007,109(10):858-861.
  • 10Sathasivam S. Current and emerging treatments for te management of myasthenia gravis [J]. Ther Clin Risk Manag, 2011, 7(2): 313-323.

引证文献10

二级引证文献30

广东医学
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部